Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Other Non-Current Liabilities (2019 - 2025)

Historic Other Non-Current Liabilities for BridgeBio Pharma (BBIO) over the last 7 years, with Q3 2025 value amounting to $679000.0.

  • BridgeBio Pharma's Other Non-Current Liabilities rose 8010.61% to $679000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $679000.0, marking a year-over-year increase of 8010.61%. This contributed to the annual value of $286000.0 for FY2024, which is 9492.37% down from last year.
  • As of Q3 2025, BridgeBio Pharma's Other Non-Current Liabilities stood at $679000.0, which was up 8010.61% from $545000.0 recorded in Q2 2025.
  • BridgeBio Pharma's 5-year Other Non-Current Liabilities high stood at $28.6 million for Q2 2022, and its period low was $286000.0 during Q4 2024.
  • Moreover, its 5-year median value for Other Non-Current Liabilities was $11.8 million (2023), whereas its average is $12.4 million.
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first surged by 31515.91% in 2021, then crashed by 9680.1% in 2024.
  • Over the past 5 years, BridgeBio Pharma's Other Non-Current Liabilities (Quarter) stood at $22.1 million in 2021, then increased by 20.73% to $26.6 million in 2022, then crashed by 78.85% to $5.6 million in 2023, then tumbled by 94.92% to $286000.0 in 2024, then skyrocketed by 137.41% to $679000.0 in 2025.
  • Its Other Non-Current Liabilities stands at $679000.0 for Q3 2025, versus $545000.0 for Q2 2025 and $352000.0 for Q1 2025.